lapatinib has been researched along with ponatinib in 8 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (ponatinib) | Trials (ponatinib) | Recent Studies (post-2010) (ponatinib) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 538 | 34 | 519 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
| Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Airhart, S; Bult, C; Davis, RR; de Vere White, RW; Gandara, DR; Ghosh, PM; Gill, P; Keck, J; Lin, TY; Liu, E; Pan, CX; Tepper, CG; Zhang, H | 1 |
| Carter, DR; Chen, J; Cheung, BB; Ciampa, OC; Fletcher, JI; Ho, N; Kamili, A; Liu, PY; Liu, T; Marshall, GM; Sun, Y; Tee, AE; Wong, M | 1 |
1 review(s) available for lapatinib and ponatinib
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 trial(s) available for lapatinib and ponatinib
| Article | Year |
|---|---|
Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.
Topics: Animals; Female; Heterografts; Humans; Imidazoles; Lapatinib; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Pyridazines; Quinazolines; Quinolines; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |
6 other study(ies) available for lapatinib and ponatinib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Highly predictive and interpretable models for PAMPA permeability.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine | 2017 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States | 2020 |
Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; DNA-Binding Proteins; Down-Regulation; Drug Synergism; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lapatinib; N-Myc Proto-Oncogene Protein; Neuroblastoma; Phenylenediamines; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; RNA-Binding Proteins | 2020 |